Trinity Delta Lighthouse: HUTCHMED
Trinity Delta view: HUTCHMED’s sustainable profitability aim is underpinned by continued commercial and R&D execution. Geographic expansion ex-China, new indications for current China products, and potential new product approvals will support near-term growth, while M&A and/or in-licensing have a role in the mid-term. Accelerated investment in the highly attractive ATTC platform, which could address a wide range of oncology indications with sizeable market potential, should drive longer-term prospects. Our most recent HUTCHMED valuation was $5.98bn/£4.66bn/ HK$46.61bn, or $34.26/ADS and 548p/HK$53.4 per share.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.